HPV vaccine trial to reduce virus spread in women
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born female and are between 18 and 29 years old.
- You live in the Kambia district (or a nearby area) and plan to stay for the next 12 months.
- You are willing to be tested for HIV and must test negative.
- You are not pregnant and will use effective birth control if sexually active.
- You have not had an HPV vaccine before and agree to receive one dose of Gardasil 9 if chosen for the vaccine group.
- You can give urine, blood, and cervical samples and understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This study tests giving the HPV vaccine along with HPV screening to quickly reduce HPV infection and cervical cancer. It is for women aged 23-29 in Rwanda who choose to join.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
This trial tests how well the HPV vaccine triggers immune memory in women who may have been exposed to HPV. It could help protect against future HPV infections and related cancers.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.